US Food and Drug Administration (USFDA) has classified the Alembic Pharmaceuticals General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI).
Inspection at the Panelav plant was conducted by USFDA from 9th March, 2020 to 13th March, 2020. VAI means USFDA accepted the Company’s response to its observations.
A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
On a consolidated basis, the pharmaceutical company's net profit rose 88.10% to Rs 233.25 crore on a 30.19% increase in the net sales to Rs 1,206.83 crore in Q4 March 2020 over Q4 March 2019. The result was announced on 23 April 2020.
